多伦多病童医院脑干胶质瘤PPT.ppt
《多伦多病童医院脑干胶质瘤PPT.ppt》由会员分享,可在线阅读,更多相关《多伦多病童医院脑干胶质瘤PPT.ppt(97页珍藏版)》请在三一文库上搜索。
1、Paediatric Brainstem Tumours,among brainstem gliomas,A tectal glioma B focal midbrain tumor C focal intrinsic pontine glioma D dorsal/exophytic glioma E diffuse intrinsic pontine glioma* F focal medullary glioma G cervicomedullary glioma,A Few Important Distinctions,* a form of high grade glioma, ak
2、in to anaplastic astrocytoma or glioblastoma multiforme,Brainstem Gliomas,Low grade gliomas Not common! Focal exophytic Cervicomedullary tumours Diffuse Intrinsic Brainstem Tumours 10-15% of all brain tumours 25% of the mortality by brain tumour in children Atypical brainstem tumours Atypical brains
3、tem lesions Brainstem tumours in infants,Low grade glioma of the brainstem,Clinical symptoms Often long presenting history Progressive motor deficit or ataxia Cranial nerve deficits are infrequent Radiological characteristics Majority are focal and exophitic Enhancing tumours,Diagnosis and managemen
4、t of LGG,Need a biopsy/resection Often pilocytic Result needs to be correlated with the clinical and radiological characteristics Surgical resection (even incomplete) can lead to sustained remission or cure,August 2001,August 2006,October 2014,August 2000,December 2001,Diagnosis and management of LG
5、G,Postoperative management Either immediately after surgery Or at the time of progression Radiation or chemotherapy? No clear answer Radiation still standard treatment Chemotherapy works,December 2001,December 2002,Low grade glioma of the brainstem: chemotherapy with weekly vincristine and carboplat
6、in,Diagnosis (11/2013),1/2015 (one year of VBL),BRAF V600 mutated tumour,The diffuse intrinsic brainstem tumours,15-20% of all paediatric brain tumours Typical clinical presentation Short history (6 3 1 month) At least 2 of the 3 signs/symptoms Cranial nerve deficit Long tracts signs Ataxia Not ofte
7、n reported, but nearly always present: behavioral changes Laughter (night) School phobia Sadness,The diffuse intrinsic brainstem tumours,Cranial nerve deficits Ocular motor deficits (CN 6 the most common) Facial weakness Unilateral deafness Swallowing disorders Nystagmus often present,The diffuse in
8、trinsic brainstem tumours,Radiology More than 50% of the pons Hypodense Little/no enhancement,Typical DPG,Typical BSG,The atypical brainstem tumours,Atypical by clinical presentation Long history and imaging suggesting diffuse pontine glioma Atypical by imaging Focal enhancing tumour and short sympt
9、oms Atypical by pathology Short symptoms and low grade pathology Discrepancy symptoms/radiology/pathology,13 year old 10 month history of progressive right sided weakness, (R) CN 7 and 8 Grade 2 on histolology,17 year old 12 month history of dizziness when lying down No CN deficit, no Long tract sig
10、n, no ataxia,The atypical brainstem tumours,Always treat as a diffuse intrinsic glioma with upfront focal radiation Chemotherapy to discuss case by case,The atypical brainstem lesions,No correlation between clinical and radiological finding Do not treat unless evidence of progression,11 year-old,Jan
11、uary 2004,2010 (18 years old),January 2004,2010,Brainstem tumours in babies,Not good (except LGG) Not always gliomas,1 day old PM: PNET,1 day old No PM,LGG of infancy,4 month old Pilocytic Astrocytoma On chemo,How to distinguish?,Clinical context Clinical exam Radiology Spectroscopy Pathology,DPG,LG
12、G,Focal HGG,DPG,LGG,2 year-old, 5 months history of ataxia and gaze palsy,Biopsy: low grade astrocytoma,3 years old, NF1,10/2012,7/2013,3 years old Mild hemiparesis Biopsy: infiltrative astrocytoma (grade 2),9/2012,10/2016,MALIGNANT GLIOMA OF PONS CANADIAN CASES BY YEAR,Management of DIPG,Role of su
13、rgery No role has been demonstrated Does not affect treatment Does not influence survival Can be misleading Risks are significant Ongoing discussions Biology?,Short symptoms ( 1 month) Classical triad Cranial nerve deficits Long tract signs Ataxia NO NEED FOR BIOPSY! TREATMENT SHOULD BE STARTED ASAP
14、 (within 48 hours),Management,Radiation The standard treatment Aims: to improve symptoms (the best palliative treatment) Timing: ASAP + (within 24-48 hours) Technique: focal, opposed parallel fields, standard fractionation Dose: 54 Gy in 30 fractions,Diffuse Pontine Glioma,Standard RT 50-54 Gy in 1.
15、8 Gy Daily fractions,Current trend to move to conformal techniques,Management,Radiation Role of other techniques? Hyperfractionation: POG and CCSG experience Several studies have been conducted in the late 80s/early 90s Doses up to 84 Gy No evidence of survival benefit Some evidence of increased tox
16、icity,Hyperfractionation: results of prospective studies,Freeman et al, POG 9239, IJROBP1999,Management,Radiation Role of other techniques? Gamma knife: BSG often listed as one of the tumours eligible for gamma knife No series reported No rational for this technique (would cause brainstem necrosis),
17、Management,Radiation Role of other techniques? Radiosensitising agents Gadolinium texaphyrin: COG phase I ongoing, should be completed soon and followed by a phase II study Topotecan: phase I POG study completed 4 years ago, published in 2003 in Neuro-oncology. Suggest improvement in median survival
18、. Phase II study planned,Hypofractionation,Less sessions Higher dose per fraction (13 or 15 instead of 30) Usually offered as a palliative option, in particular in elderly patients Has been suggested and tested in patients with DIPG Randomised study published in 2014 (Cairo) No significant differenc
19、e with conventional radiation,Hypofractionaltion,54 Gy in 30 fractions versus 39 Gy in 13 fractions,Zhagloul et al Radiotherapy & Oncology 2014,Management,Steroids A major role Always the lowest possible dose to limit the side effects (quality of life) Be careful during the first week (significant r
20、eactions to the first sessions of radiation) With caution at the time of progression,Diffuse brainstem Gliomas Role of chemotherapy,Numerous studies Upfront or at the time of progression Single agent or combinations Response rate low 0 to 20% No drug or combination seems to have a significant activi
21、ty,Diffuse brainstem Gliomas Role of chemotherapy,One randomised study CCG 943 Conducted in the pre-MRI era (all BSG) Radiation + Chemotherapy (vincristine-CCNU) Overall survival 22% at 2 years No evidence of benefit with chemotherapy,Diffuse brainstem Gliomas Role of chemotherapy,Other studies Conv
22、entional chemotherapy Cisplatin Carboplatin before and/or during radiation Etoposide oral High dose chemotherapy SFOP experience with high dose busulfan and thiotepa,Diffuse brainstem Gliomas: Other agents,Other studies Interferon (CCG study) Tamoxifen (Brazilian study) Thalidomide (Boston) Small mo
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 多伦 多病 医院 脑干 胶质 PPT
链接地址:https://www.31doc.com/p-3039027.html